Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Long-Term Advantages May Not Endure After Early Tight Control in Psoriatic Arthritis

Key clinical point: Patients in a psoriatic arthritis study comparing tight control and standard care showed no significant difference in disease activity 5 years later.

Major finding: At 5 years after the end of the TICOPA trial, 69% in the tight control group vs. 76% in the standard care group were considered to be in low disease activity.

Study details: The data come from a follow-up of 110 patients from the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) study.

Disclosures: The current study was funded by the National Institute for Health Research infrastructure at Leeds and Oxford (England). The original TICOPA study was funded by Arthritis Research UK (now called Versus Arthritis) and Pfizer. Some of the investigators disclosed financial relationships with companies that market drugs for PsA.

Citation:

Coates LC et al. Rheumatology. 2019 Aug 31. doi: 10.1093/rheumatology/kez369.